Tag: neuropathic pain market trends

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Neuropathic Pain Market Size Forecast: How Large Could The Market Become By 2030?

The market for neuropathic pain treatments has experienced significant expansion. Projections indicate a rise from $5.78 billion in 2025 to $6.2 billion in 2026, reflecting a compound annual growth rate of 7.3%. This past growth trajectory has been fueled by several factors, including the increasing incidence of diabetes, the early integration of antidepressant and anticonvulsant medications into treatment plans, heightened public and medical understanding of neuropathic pain, the advent of opioid-based therapeutic options, and the initial utilization of medical imaging for diagnostic purposes.

Anticipate a robust expansion within the neuropathic pain market, projected to reach $8.48 billion by 2030, reflecting a compound annual growth rate of 8.1% over the upcoming years. This upward trajectory is fueled by a confluence of factors, including a notable pivot towards non-opioid treatment modalities, an escalating need for tailored pain management strategies, a broader acceptance of complementary therapeutic interventions, heightened investments in groundbreaking diagnostic tools, and the progressive development of sophisticated multimodal treatment frameworks. Key developments shaping this period encompass the increasing embrace of integrated multimodal therapeutic approaches, a heightened demand for pain management solutions that bypass opioids, the growing integration of physical and psychological therapies, the enhancement of early detection capabilities through advanced imaging, and a concentrated effort on addressing diabetic neuropathy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Neuropathic Pain Market Industry Drivers: What Is Driving Revenue Growth?

The expanding incidence of chronic pain is poised to stimulate advancement in the neuropathic pain market during the forecast period, as persistent discomfort lasting over three months, identified as chronic pain, impacts a considerable segment of individuals and detrimentally affects their overall well-being. This surge in chronic pain occurrences is attributed to demographic shifts such as an aging populace, instances of nerve damage, and long-term health conditions including diabetes. Treatments for neuropathic pain contribute to public health objectives by addressing nerve-related impairments, alleviating symptom severity, and enhancing patients’ functional capacity in their daily lives. Illustrating this trend, data released in November 2024 by the Centers for Disease Control and Prevention (CDC), a leading US health protection organization, indicated that in 2023, adult chronic pain prevalence stood at 24.3%, with high-impact chronic pain affecting 8.5% of adults, consequently representing 34.9% of those experiencing chronic pain; this data also highlighted disproportionately higher rates among women, American Indian and Alaska Native adults, and individuals aged 65 and above. Consequently, the escalating prevalence of chronic pain serves as a primary catalyst for the growth observed in the neuropathic pain market.

Neuropathic Pain Market Segment Landscape: Which Areas Lead Market Development?

The neuropathic pain market covered in this report is segmented –

1) By Treatment: Medications, Multimodal Therapy

2) By Diagnosis: Imaging, Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

#Neuropathic Pain Market Growth Trends: What Is Influencing The Future Outlook?

Key players within the neuropathic pain sector are integrating artificial intelligence to elevate diagnostic precision, personalize therapeutic approaches, enable continuous patient observation, accelerate pharmaceutical development, and harness data-driven intelligence, all with the aim of improving patient results and optimizing pain management protocols. A notable illustration came in March 2023, when Nevro Corp., a medical device manufacturer headquartered in the United States, introduced its Senza HFX iQ spinal cord stimulation (SCS) system. This groundbreaking system leverages artificial intelligence (AI) to fine-tune pain alleviation specifically for each individual. Comprising the HFX iQ Implantable Pulse Generator (IPG), the HFX Trial Stimulator, a charger, and the HFX App, this integrated solution is engineered to address non-surgical back pain and painful diabetic neuropathy by dynamically adjusting to patient feedback and physiological responses. It incorporates a proprietary algorithm developed from substantial patient data, empowering patients to modify their pain relief regimen through a mobile application. The digital framework supporting this system facilitates the gathering of data and offers opportunities for future enhancements. Ultimately, this technology strives to boost the effectiveness of pain relief through a combination of reliability and individualized care, representing a substantial stride forward in SCS treatment.

Neuropathic Pain Market Industry Leaders And Market Competition

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Access The Complete Neuropathic Pain Market Report:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Neuropathic Pain Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the neuropathic pain market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Neuropathic Pain Market By 2030?

The neuropathic pain market has seen robust expansion in recent years. It is forecast to grow from $5.78 billion in 2025 to $6.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This past growth is attributable to an increase in diabetes prevalence, the early embrace of antidepressants and anticonvulsants, enhanced understanding of neuropathic pain conditions, the creation of opioid-based treatments, and the initial application of imaging for diagnosis.

The neuropathic pain market is anticipated to experience robust growth in the coming years. It is projected to expand to $8.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This expansion throughout the forecast period stems from a rising inclination towards non-opioid treatments, an increasing need for individualized pain management, the broader utilization of complementary therapies, enhanced investment in diagnostic innovations, and the development of advanced multimodal treatment solutions. Prominent trends for the forecast duration encompass the growing acceptance of multimodal therapy approaches, an escalating demand for non-opioid pain management, the increasing incorporation of physical and psychological therapies, the widening scope of early diagnosis through imaging techniques, and a heightened focus on diabetic neuropathy treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Which Core Factors Are Supporting The Expansion Of The Neuropathic Pain Market?

The expansion of the neuropathic pain market is anticipated to be driven by the increasing occurrence of chronic pain. This condition, defined as persistent discomfort extending for three months or longer, affects a considerable segment of the population, profoundly diminishing their quality of life. The surge in chronic pain cases stems from contributing factors such as an aging demographic, nerve damage, and long-term health issues including diabetes. Neuropathic pain treatments contribute to public health by addressing nerve dysfunction, alleviating symptoms, and enhancing patients’ ability to perform daily activities. To illustrate, data released by the Centers for Disease Control and Prevention (CDC), a US-based nation’s health protection agency, in November 2024, indicated that in 2023, 24.3% of adult populations experienced chronic pain, with 8.5% suffering from high-impact chronic pain. This figure equates to 34.9% among those with chronic pain, with women, American Indian and Alaska Native adults, and individuals aged 65 years and older exhibiting particularly elevated rates. Consequently, the increasing prevalence of chronic pain is serving as a catalyst for the neuropathic pain market.

What Are The Core Segment Classifications In The Neuropathic Pain Market?

The neuropathic pain market covered in this report is segmented –

1) By Treatment: Medications, Multimodal Therapy

2) By Diagnosis: Imaging, Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

Which Trends Are Expected To Shape The Neuropathic Pain Market?

Major companies operating in the neuromyelitis optica spectrum disorder market are actively pursuing the creation of innovative products, such as long-acting complement inhibitors, to elevate treatment effectiveness and enhance patient well-being. These long-acting complement inhibitors function by inhibiting the complement system for an extended duration, thereby curbing inflammation and nerve damage in neuromyelitis optica spectrum disorder (NMOSD). They contribute to reducing occurrences of relapses and aiding in sustained disease management. For instance, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical firm, and AstraZeneca, a UK-based pharmaceutical company, secured regulatory clearance for ULTOMIRIS (ravulizumab-cwvz) for treating adults diagnosed with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). This approval establishes Ultomiris as the first and only long-acting C5 complement inhibitor accessible for NMOSD treatment. This authorization was substantiated by findings from the Phase III CHAMPION-NMOSD trial, where Ultomiris exhibited a 98.6% decrease in relapse risk over 73 weeks when compared to a placebo. Participants in the trial did not encounter any relapses, and no novel safety issues emerged.

Who Are The Companies Shaping The Neuropathic Pain Market Landscape?

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Access The Complete Neuropathic Pain Market Report:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Which Region Holds The Largest Share In The Neuropathic Pain Market?

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neuropathic Pain Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp

Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company

Optic Atrophy Management Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Peripheral Neuropathy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Retinal Disorder Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Neuropathic Pain Market During 2026–2030?

The neuropathic pain market has shown substantial growth in recent years. It is anticipated to expand from $5.78 billion in 2025 to $6.2 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to factors such as the rising prevalence of diabetes, the early adoption of antidepressants and anticonvulsants, increased awareness of neuropathic pain conditions, the development of opioid-based treatments, and the initial use of imaging for diagnosis.

The neuropathic pain market is projected for substantial expansion over the next few years, set to reach $8.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This anticipated growth during the forecast period stems from a growing inclination towards non-opioid treatments, an increasing need for personalized pain management, the broader use of complementary therapies, rising investments in diagnostic innovations, and the development of advanced multimodal treatment solutions. Significant trends observed in this period include the rising adoption of multimodal therapy approaches, increasing demand for non-opioid pain relief, the growing integration of physical and psychological therapies, an expansion of early diagnosis through imaging techniques, and an elevated focus on diabetic neuropathy treatment.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Which Drivers Are Supporting The Neuropathic Pain Market Growth?

The increasing incidence of chronic pain is projected to drive expansion within the neuropathic pain market in the future. This condition is characterized by persistent discomfort that endures for at least three months, affecting a considerable segment of the populace and markedly diminishing their quality of life. The surge in chronic pain incidents stems from factors including aging populations, nerve damage, and long-term health issues such as diabetes. Treatments for neuropathic pain contribute to public health by addressing nerve dysfunction, alleviating symptoms, and enhancing patients’ everyday activities. As an illustration, in November 2024, figures released by the Centers for Disease Control and Prevention (CDC), the US national health protection agency, indicated that in 2023, adult populations had a 24.3% prevalence of chronic pain and an 8.5% prevalence of high-impact chronic pain, which equated to 34.9% among individuals experiencing chronic pain, with women, American Indian and Alaska Native adults, and those aged 65 years and older demonstrating particularly elevated rates. Consequently, the growing prevalence of chronic pain is a key factor boosting the neuropathic pain market.

How Is The Neuropathic Pain Market Broken Down By Segment Categories?

The neuropathic pain market covered in this report is segmented –

1) By Treatment: Medications, Multimodal Therapy

2) By Diagnosis: Imaging, Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

Which Trends Are Expected To Impact The Neuropathic Pain Market?

Leading companies in the neuropathic pain market are integrating artificial intelligence technologies for advanced diagnostics, personalized treatment strategies, real-time patient monitoring, new drug discovery, and data-driven insights, all aimed at improving patient outcomes and refining pain management approaches. For instance, in March 2023, Nevro Corp., a US-based medical device company, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology employs artificial intelligence (AI) to customize pain relief for individual patients. The system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is designed to treat non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It utilizes a unique algorithm built on extensive patient data and allows patients to adjust their pain relief program using a smartphone application. The system’s digital environment permits data collection and potential future updates. The technology aims to enhance the consistency and personalization of pain relief, signifying a major advancement in SCS therapy.

Which Players Are Present In The Neuropathic Pain Market Space?

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Get The Full Neuropathic Pain Market Report:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Which Region Holds The Highest Market Share In The Neuropathic Pain Market?

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neuropathic Pain Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company

Optic Atrophy Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Peripheral Neuropathy Market Report

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Retinal Disorder Treatment Market Report

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Neuropathic Pain Market Projected To Become By 2030 Based On Its 2026 Valuation?

The neuropathic pain market has seen significant expansion over recent years. Projections indicate its value will increase from $5.78 billion in 2025 to $6.2 billion by 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical growth is attributable to factors such as the increasing incidence of diabetes, the widespread adoption of antidepressants and anticonvulsants, heightened awareness concerning neuropathic pain conditions, the evolution of opioid-based treatments, and the initial integration of imaging for diagnostic purposes.

The neuropathic pain market size is projected for substantial expansion over the coming years, reaching $8.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period is fueled by a burgeoning shift towards non-opioid treatments, an escalating demand for personalized pain management strategies, the broadening application of complementary therapies, increased funding in diagnostic innovations, and the creation of sophisticated multimodal treatment options. Key trends anticipated in this period encompass the growing embrace of multimodal therapy approaches, a heightened need for non-opioid solutions for pain, the increasing incorporation of physical and psychological therapies, advancements in early diagnosis facilitated by imaging techniques, and a sharpened focus on addressing diabetic neuropathy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Which Market Drivers Are Supporting The Expansion Of The Neuropathic Pain Market?

The increasing occurrence of chronic pain is anticipated to stimulate the expansion of the neuropathic pain market in the future. Chronic pain, characterized as discomfort enduring for at least three months, impacts a considerable segment of the population and substantially diminishes their quality of life. The rise in chronic pain instances stems from factors including aging demographics, nerve injury, and long-term conditions such as diabetes. Therapies for neuropathic pain contribute to public health by addressing nerve malfunctions, alleviating symptoms, and enhancing patients’ everyday activities. For example, data released by the Centers for Disease Control and Prevention (CDC), a US-based nation’s health protection agency, in November 2024, indicated that adult populations in 2023 faced a 24.3% prevalence of chronic pain and an 8.5% prevalence of high-impact chronic pain, which is equivalent to 34.9% among those suffering from chronic pain, with women, American Indian and Alaska Native adults, and individuals aged 65 years and older exhibiting particularly elevated rates. Consequently, the growing incidence of chronic pain is fueling the neuropathic pain market.

What Segment Groups Are Identified Within The Neuropathic Pain Market?

The neuropathic pain market covered in this report is segmented –

1) By Treatment: Medications, Multimodal Therapy

2) By Diagnosis: Imaging, Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

What Trends Are Affecting The Expansion Of The Neuropathic Pain Market?

Leading companies in the neuropathic pain market are integrating artificial intelligence technologies for enhanced diagnosis, personalized treatment strategies, continuous monitoring, drug discovery, and data-driven insights to improve patient outcomes and refine pain management approaches. For instance, in March 2023, Nevro Corp., a US-based medical device company, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology leverages artificial intelligence (AI) to customize pain relief for individual patients. The system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is engineered to address non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It utilizes a distinctive algorithm developed from extensive patient data and allows patients to modify their pain relief program using a smartphone app. The system’s digital ecosystem facilitates data collection and potential updates. This technology aims to elevate pain relief through consistency and personalization, signifying a notable advancement in SCS therapy.

Which Companies Hold Significant Positions In The Neuropathic Pain Market?

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Read the full neuropathic pain market report here:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

How Is The Neuropathic Pain Market Distributed Across Key Geographic Regions?

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuropathic Pain Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp

Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company

Optic Atrophy Management Global Market Report

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Peripheral Neuropathy Global Market Report

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Retinal Disorder Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neuropathic pain market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Neuropathic Pain Market in 2026, and what figure is it projected to hit by 2030?

The neuropathic pain market has exhibited strong growth over recent years. It is forecast to grow from $5.78 billion in 2025 to $6.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The expansion observed in the historical period can be attributed to an increasing prevalence of diabetes, the early adoption of antidepressants and anticonvulsants, enhanced awareness of neuropathic pain conditions, the creation of opioid-based treatments, and the initial utilization of imaging for diagnosis.

The market for neuropathic pain is projected to experience substantial growth over the coming years, anticipated to reach $8.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period can be attributed to a growing preference for non-opioid treatments, the increasing need for individualized pain management, the wider adoption of complementary therapies, greater investment in diagnostic breakthroughs, and the creation of sophisticated multimodal treatment approaches. Prominent trends expected during this period involve a surge in multimodal therapy uptake, a heightened call for non-opioid pain relief, increased integration of physical and psychological therapies, advancements in early diagnosis via imaging methods, and an intensified focus on managing diabetic neuropathy.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Which Drivers Are Affecting Market Participation In The Neuropathic Pain Market?

The increasing occurrence of chronic pain is anticipated to fuel the expansion of the neuropathic pain market moving ahead. Chronic pain, characterized as ongoing discomfort persisting for at least three months, affects a considerable segment of the population and profoundly impacts their quality of life. This rise in chronic pain instances stems from factors including aging demographics, nerve injuries, and long-term health conditions such as diabetes. Therapies for neuropathic pain contribute to public health by addressing nerve dysfunction, alleviating symptoms, and enhancing patients’ daily activities. As an illustration, data released in November 2024 by the Centers for Disease Control and Prevention (CDC), a US-based national health protection agency, indicated that in 2023, adult populations experienced a 24.3% prevalence of chronic pain and an 8.5% prevalence of high-impact chronic pain, which translates to 34.9% among those with chronic pain, with women, American Indian and Alaska Native adults, and individuals aged 65 years and older exhibiting particularly elevated rates. Consequently, the growing prevalence of chronic pain is stimulating the neuropathic pain market.

What Segment Categories Are Covered In The Neuropathic Pain Market?

The neuropathic pain market covered in this report is segmented –

1) By Treatment: Medications, Multimodal Therapy

2) By Diagnosis: Imaging, Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

How Are New Market Trends Shaping The Landscape Of The Neuropathic Pain Market?

Companies operating within the neuropathic pain market are increasingly integrating artificial intelligence technologies for improved diagnosis, personalized treatment plans, real-time patient monitoring, drug discovery, and data-driven insights. These efforts are aimed at enhancing patient outcomes and refining pain management strategies. For instance, in March 2023, Nevro Corp., a medical device company based in the US, introduced its Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology harnesses artificial intelligence (AI) to customize pain relief for individual patients. The system, which comprises the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is designed to address non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It utilizes a distinct algorithm derived from extensive patient data, enabling patients to modify their pain relief program via a smartphone application. The system’s digital platform supports data collection and potential updates. The objective of this technology is to elevate pain relief through consistency and personalization, representing a notable advancement in SCS therapy.

Which Leading Companies Dominate The Neuropathic Pain Market Share?

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Neuropathic Pain Market?

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neuropathic Pain Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp

Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company

Keloids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Actinic Keratosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-treatment-global-market-report

Hypertrophic And Keloid Scar Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypertrophic-and-keloid-scar-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model